AMYOTROPHIC LATERAL SCLEROSIS (ALS)
Recruiting for Phase 1/2 Study
We are currently recruiting for a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants.
The trial is open in Australia and soon to be in the USA. The FDA has approved the U.S. IND (IND 154637) and granted Orphan Drug Designation for SPG302 for the treatment of ALS.
Upcoming U.S. Clinical Trials
NCT05882695
Status: not yet recruiting; please continue to check the status at ClinicalTrials.gov
Location
Boston, Massachusetts at Mass General Brigham
Contact: Mary C McCormick
mmccormack12@mgh.harvard.edu
For additional information, visit ClinicalTrials.gov
Clinical Trial Sites are Open in Australia:
NCT05882695
Status: Recruiting
Locations
Dr. Schultz at Flinders Medical Center in Adelaide, SA.
Contact: Dr. David Schultz at Flinders Medical Center
david.schultz@sa.gov.au
Dr Henderson at the Royal Brisbane and Woman’s Hospital in Brisbane, Queensland
Contact: Sue Heggie at Royal Brisbane and Woman’s Hospital
susan.heggie@health.qld.gov.au
Dr Rowe at Macquarie Hospital in North Ryde, N.S.W.
Contact: Richard Gan at Macquarie
richard.gan@mq.edu.au
